Cargando…

Antithrombotic treatment switching in elderly patients with atrial fibrillation and the risk of thromboembolism, bleeding, and cardiac death

BACKGROUND: Risks of antithrombotic switching is not investigated in elderly atrial fibrillation patients. OBJECTIVES: To investigate the effectiveness and safety of antithrombotic treatment and switching of antithrombotic treatment in elderly patients (aged 75 years or older) with atrial fibrillati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehrlinder, Hanne, Orsini, Nicola, Modig, Karin, Wallén, Håkan, Gigante, Bruna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596606/ https://www.ncbi.nlm.nih.gov/pubmed/36313983 http://dx.doi.org/10.1002/rth2.12823

Ejemplares similares

Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort
por: Ehrlinder, Hanne, et al.
Publicado: (2020)

Is the association of QTc with atrial fibrillation and stroke in cohort studies a matter of time?
por: Radnahad, Navid, et al.
Publicado: (2022)

Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?
por: Guo, Yutao, et al.
Publicado: (2010)

Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
por: Komen, Joris J, et al.
Publicado: (2019)

IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation
por: Ziegler, Louise, et al.
Publicado: (2021)

Correction: IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation
por: Ziegler, Louise, et al.
Publicado: (2022)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation: Results From the Swedish AMORIS Cohort
por: Ding, Mozhu, et al.
Publicado: (2023)

Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation
por: da Silva, Rose Mary Ferreira Lisboa, et al.
Publicado: (2017)

The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report
por: Hammer, Andreas, et al.
Publicado: (2020)

Lipid levels in midlife and risk of atrial fibrillation over 3 decades—Experience from the Swedish AMORIS cohort: A cohort study
por: Ding, Mozhu, et al.
Publicado: (2022)

Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis
por: Menozzi, Mila, et al.
Publicado: (2012)

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
por: Suárez Fernández, Carmen, et al.
Publicado: (2015)

Pilot study of peripheral blood chemokines as biomarkers for atrial fibrillation-related thromboembolism and bleeding in elderly patients
por: Tai, Meihui, et al.
Publicado: (2022)

Erratum: Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
por: Fernández, Carmen Suárez, et al.
Publicado: (2015)

Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice
por: An, JaeJin, et al.
Publicado: (2015)

In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation
por: Chang, San-Shuai, et al.
Publicado: (2018)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Left Atrial Diameter in the Prediction of Thromboembolic Event and Death in Atrial Fibrillation
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
por: Xiang, Wei, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy
por: Baturina, Olga, et al.
Publicado: (2023)

The use of antithrombotics in patients presenting with stroke and atrial fibrillation
por: Burgess, Carl, et al.
Publicado: (2007)

Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
por: Abcede, Hermelinda G., et al.
Publicado: (2010)

The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019)

Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation
por: Bang, Oh Young, et al.
Publicado: (2022)

Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community
por: Joosten, L. P. T., et al.
Publicado: (2022)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation
por: Cameron, Chris, et al.
Publicado: (2014)

Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study
por: Staerk, Laila, et al.
Publicado: (2015)

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice
por: Sabir, Ian N, et al.
Publicado: (2013)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
por: Wei, Lili, et al.
Publicado: (2020)

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
por: Bor, Wilbert, et al.
Publicado: (2020)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Moustafa, Abdelmoniem, et al.
Publicado: (2019)

Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2022)

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
por: Magnocavallo, Michele, et al.
Publicado: (2020)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study
por: Al-Najar, Mahasen, et al.
Publicado: (2023)

Stroke prevention and guideline adherent antithrombotic treatment in elderly patients with atrial fibrillation: A real-world experience
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04ptgb25fumb04lkg2ol35p96h